Crescent Biopharma filings document a clinical-stage oncology biotechnology issuer with ordinary shares listed on Nasdaq. The company’s Form 8-K reports furnish quarterly and annual financial results, business highlights, and pipeline updates involving CR-001, ADC programs, and collaboration activity.
Its SEC record also includes a definitive proxy statement covering governance, executive compensation, equity awards, shareholder voting matters, and board-related disclosures. Registration statement materials describe the company’s business, capitalization, preferred stock, warrants, convertible instruments, risk factors, and public-company structure.
CRESCENT BIOPHARMA, INC. (CBIO) reported that officer Ryan Lynch, its Treasurer, Senior Vice President of Finance and Chief Accounting Officer, sold 240 Ordinary Shares on September 16, 2026 at a weighted average price of $17.90 per share in an open-market or private transaction. According to the company’s disclosure, these shares were automatically sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted on December 15, 2025 and were carried out under a Rule 10b5-1 instruction adopted on February 25, 2026 solely to cover taxes related to that vesting. Following this sale, Lynch directly holds 13,631 Ordinary Shares.
CRESCENT BIOPHARMA, INC. (CBIO) reported that Chief Scientific Officer Jan Pinkas sold 658 Ordinary Shares on September 16, 2026 at a weighted average price of $17.90 per share. The shares were automatically sold to satisfy tax withholding obligations upon settlement of previously granted restricted stock units, under a Rule 10b5-1 trading instruction. Following this sale, Pinkas directly holds 21,581 Ordinary Shares.
CRESCENT BIOPHARMA, INC. (CBIO) reported that its Chief Medical Officer, Ellie Eunkyung Im, sold 623 Ordinary Shares on September 16, 2026 at a weighted average price of $17.90 per share, leaving her with 21,446 shares held directly.
According to the company’s disclosure, these shares were automatically sold to satisfy tax withholding obligations arising from the settlement of restricted stock units granted on December 15, 2025, and were effected pursuant to a Rule 10b5-1 trading instruction adopted on February 25, 2026. The price reflects multiple trades between $17.10 and $19.17 per share.
CRESCENT BIOPHARMA, INC. (CBIO) reported that Chief Financial Officer Richard William Scalzo sold 568 Ordinary Shares on September 16, 2026 in an open-market transaction at a weighted average price of $17.90 per share. The shares were automatically sold to satisfy tax withholding obligations from vesting restricted stock units under a Rule 10b5-1 trading instruction. Following this sale, he directly holds 19,730 Ordinary Shares.
CRESCENT BIOPHARMA, INC. (CBIO) reported that its General Counsel and Corporate Secretary, Barbara Harlin Bispham, sold 620 Ordinary Shares on September 16, 2026, primarily to satisfy tax withholding obligations on vesting restricted stock units. The weighted average sale price was $17.90 per share, with prices ranging from $17.10 to $19.17. After this tax-related sale, she directly holds 18,710 Ordinary Shares. The transaction was executed under a Rule 10b5-1 trading instruction adopted on February 25, 2026.
CRESCENT BIOPHARMA, INC. (CBIO) reported that Chief Executive Officer and director Joshua T. Brumm sold Ordinary Shares in two transactions, totaling 9,447 shares, on September 16 and September 18, 2026. According to the company’s disclosure, the shares were automatically sold to satisfy tax withholding obligations upon settlement of previously granted restricted stock units and were effected under a Rule 10b5-1 trading instruction adopted on February 28, 2026.
CRESCENT BIOPHARMA, INC. (CBIO) reported that President and COO Jonathan McNeill sold a total of 4,570 Ordinary Shares in open market transactions on September 16 and 18, 2026. The sales were made under a Rule 10b5-1 trading instruction adopted on February 25, 2026 and were executed solely to cover tax withholding obligations tied to vesting restricted stock units.
Crescent Biopharma, Inc. (CBIO) is the issuer for a Rule 144 notice filed for the account of Joshua T. Brumm covering proposed sales of its ordinary shares.
The notice reports a planned sale of 16,775 ordinary shares, acquired through restricted stock unit vesting from the issuer on September 17, 2026 as compensation for services. It also lists sales during the past three months of 42,305 ordinary shares on June 22, 2026 for $761,257.32 and 1,610 ordinary shares on September 16, 2026 for $28,815.62. Securities information shows 9,013 ordinary shares in a Morgan Stanley Smith Barney LLC Executive Financial Services account, with an associated value of $154,843.34 and a date of September 18, 2026.
CRESCENT BIOPHARMA, INC. (CBIO) is the issuer for a notice in which officer Jonathan McNeill files to rely on Rule 144 for sales of the company’s ordinary shares. The notice describes a planned sale tied to 8,387 ordinary shares acquired through restricted stock unit vesting on September 17, 2026 for services rendered.
The filing also lists prior sales of Crescent Biopharma ordinary shares by McNeill in the preceding three months, and identifies Morgan Stanley Smith Barney LLC Executive Financial Services, with a New York address, in connection with the ordinary shares and Nasdaq listing information.
CRESCENT BIOPHARMA, INC. (CBIO) is the issuer for a planned resale of its ordinary shares under Rule 144 by Jonathan McNeill. The notice lists a proposed sale of 804 ordinary shares, with an aggregate market value of $15,115.20, on or after September 16, 2026, on Nasdaq. McNeill previously acquired 1,595 shares through restricted stock unit vesting on September 15, 2026 and sold 20,549 shares for $369,768.98 on June 22, 2026.